Abstract：Objective To study the epidemic strains and drug resistance of Ochrobactrum anthropi in bloodstream infection in children, and to provide evidence for clinical diagnosis and treatment. Methods One hundred and ninety-four strains of Ochrobactrum anthropi identified by automatic microbial identification analyzer were collected from children with Ochrobactrum anthropi sepsis in Hunan Children's Hospital from January 2010 to December 2017. The strainswere re-identified by mass spectrometry, of which 61 strains of Ochrobactrum anthropi were identified by gene sequencing, and the Results of drug resistance were statistically analyzed. Results Mass spectrometry analysis identified that 84.0% (163/194) strains of bacteria were Ochrobactrum anthropi, and other 31 strains of bacteria included Pseudochrobactrum saccharolyticum (26/31), Ochrobactrum pseudogrignonense (4/31)and Ochrobactrum intermedium (1/31). Ochrobactrum was resistant to aztreonam (100%). The resistance rates of Ochrobactrum anthropi to ampicillin, piperacillin/tazobactam, cefazolin and ceftazidime were all over 90.0%, those to levofloxacin and imipenem 0.0%, those to ciprofloxacin, amikacin and gentamicin less than 2.0%, and those to compound sulfamethoxazole and cefepime less than 21.5%. The resistance rates of Pseudochrobactrum to ampicillin and cefazolin were less than 50%, those to ceftazidime, cefepime, amikacin and gentamicin less than 10.0%, those to levofloxacin, ciprofloxacin, piperacillin/tazobactam, and compound sulfamethoxazole 0.0%, and those to imipenem were 16.1%. Gene sequencing analysis showed that Ochrobactrum anthropi carried the AmpC/R gene, but Pseudochrobactrum did not. Conclusions The main epidemic strains in children with bloodstream infection caused by Ochrobactrum in Hunan Province were Ochrobactrum anthropi, followed by Pseudochrobactrum saccharolyticum and Ochrobactrum pseudogrignonense. Traditional instruments cannot distinguish the strains of Ochrobactrum, but the drug resistance Results are different between Ochrobactrum anthropi and Pseudochrobactrum. Cefepime can be used for the treatment of Ochrobactrum anthropi infection, imipenem for severe infection in pediatric patients, and ceftazidime, cefepime, piperacillin/tazobactam for Pseudochrobactrum bacteremia infection.
李先斌, 刘健龙, 郭宽鹏, 宋春荣, 李梨平, 胡琼. 儿童血流感染病原菌人苍白杆菌的流行种系及耐药特点[J]. 实用预防医学, 2019, 26(5): 532-534.
LI Xian-bin, LIU Jian-long, GUO Kuan-peng, SONG Chun-rong, LI Li-ping, HU Qiong. Epidemic strains and drug-resistance of Ochrobactrum anthropi in bloodstream infection in children. , 2019, 26(5): 532-534.
2019, Vol. 26 
